# 89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study

> **NCT06750419** · PHASE3 · RECRUITING · sponsor: **Telix Pharmaceuticals (Innovations) Pty Limited** · enrollment: 82 (estimated)

## Conditions studied

- Clear Cell Renal Cell Carcinoma

## Interventions

- **DRUG:** 89Zr-TLX250 PET/CT

## Key facts

- **NCT ID:** NCT06750419
- **Lead sponsor:** Telix Pharmaceuticals (Innovations) Pty Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-06
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 82 (ESTIMATED)
- **Last updated:** 2024-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06750419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06750419, "89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06750419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*